Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ILK | Q13418 | 4/20 | 0.45 |
| ▸ | EGFR | P00533 | 3/20 | 0.45 |
| ▸ | ACACB | O00763 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14653334 | 0.94 | KDM4E (0.50) | ILKEGFRKDM4ERECQL | |
| SCHEMBL20969950 | 0.89 | PRSS1 (0.41) | MAPTALDH1A1 | |
| SCHEMBL6132725 | 0.88 | GAA (0.43) | ACACBMAPT | |
| SCHEMBL6133224 | 0.88 | GAA (0.43) | ACACBMAPT | |
| SCHEMBL8339774 | 0.84 | MAPT (0.52) | KDM4ERECQLMAPT | |
| SCHEMBL1391449 | 0.81 | NQO1 (0.37) | — | |
| SCHEMBL1007565 | 0.81 | LTA4H (0.53) | — | |
| SCHEMBL163688 | 0.81 | LTA4H (0.52) | ACACBMAPT | |
| SCHEMBL38655982 | 0.80 | KCNA3 (0.48) | — | |
| SCHEMBL12344398 | 0.80 | L3MBTL1 (0.46) | ILKEGFRACACBKDM4ERECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107344940-B | BTK inhibitors and uses thereof | 广东东阳光药业有限公司 | 2020-04-21 | — | — | CN | disclosed |
| US-20150232616-A1 | HYBRID BLOCK COPOLYMER MICELLES WITH MIXED STEREOCHEMISTRY FOR ENCAPSULATION OF HYDROPHOBIC AGENTS | INTEZYNE TECHNOLOGIES, INC. | 2015-08-20 | — | — | US | disclosed |
| US-8980326-B2 | Hybrid block copolymer micelles with mixed stereochemistry for encapsulation of hydrophobic agents | INTEZYNE TECHNOLOGIES, INC. (US) | 2015-03-17 | — | — | US | disclosed |
| US-8779008-B2 | Polymeric micelles for drug delivery | INTEZYNE TECHNOLOGIES, INC. (US) | 2014-07-15 | — | — | US | disclosed |
| US-20130195987-A1 | POLYMERIC MICELLES FOR DRUG DELIVERY | INTEZYNE TECHNOLOGIES, INC. (US) | 2013-08-01 | — | — | US | disclosed |
| US-8426477-B1 | Polymeric micelles for drug delivery | INTEZYNE TECHNOLOGIES, LLC (US) | 2013-04-23 | — | — | US | disclosed |
| US-8268936-B2 | Synthesis of hybrid block copolymers and uses thereof | INTEZYNE TECHNOLOGIES, INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-8263663-B2 | Azide functionalized peptide targeting groups | INTEZYNE TECHNOLOGIES, INC. (US) | 2012-09-11 | — | — | US | disclosed |
| US-20110092668-A1 | AZIDE FUNCTIONALIZED PEPTIDE TARGETING GROUPS | INTEZYNE TECHNOLOGIES, INC. (US) | 2011-04-21 | — | — | US | disclosed |
| US-20110091534-A1 | COMPOSITIONS COMPRISING POLYMERIC MICELLES FOR DRUG DELIVERY | INTEZYNE TECHNOLOGIES, INC. (US) | 2011-04-21 | — | — | US | disclosed |
| EP-1912987-A1 | HETEROCYCLIC BENZYLAMINO DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. Hoffmann-Roche AG (CH) | 2008-04-23 | — | — | EP | disclosed |
| US-20080039460-A1 | Benzamide Derivatives, Their Manufacture and Use as Pharmaceutical Agents | F. HOFFMANN-LA ROCHE AG (CH) | 2008-02-14 | — | — | US | disclosed |
| US-20080009492-A1 | Heterocyclic Carbamate Derivatives, Their Manufacture And Use As Pharmaceutical Agents | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2008-01-10 | — | — | US | disclosed |
| CN-101087786-A | Heterocyclic carbamate derivatives, their preparation and use as pharmaceutical agents | HOFFMANN LA ROCHE (CH) | 2007-12-12 | — | — | CN | disclosed |
| CN-101087787-A | Heterocyclic carbamate derivatives, their manufacture and use as pharmaceutical agents | HOFFMANN LA ROCHE (CH) | 2007-12-12 | — | — | CN | disclosed |
| EP-1833829-A2 | BENZAMIDE SUBSTITUTED IMIDAZO- AND PYRROLO-PYRIDINES AS PROTEIN KINASE INHIBITORS | F. Hoffmann-Roche AG (CH) | 2007-09-19 | — | — | EP | disclosed |
| EP-1831218-A2 | CARBAMATE SUBSTITUTED IMIDAZO- AND PYRROLO-PYRIDINES AS PROTEIN KINASE INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-09-12 | — | — | EP | disclosed |
| WO-2007014707-A1 | HETEROCYCLIC BENZYLAMINO DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-02-08 | — | — | WO | disclosed |
| WO-2006066914-A2 | CARBAMATE SUBSTITUTED IMIDAZO- AND PYRROLO-PYRIDINES AS PROTEIN KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-06-29 | — | — | WO | disclosed |
| WO-2006066913-A2 | BENZAMIDE SUBSTITUTED IMIDAZO- AND PYROLO-PYRIDINES AS PROTEIN KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130195987-A1 | POLYMERIC MICELLES FOR DRUG DELIVERY | ABCB4, CLTB, CD47 | ILK 249/4885EGFR 76/4885ACACB 1547/4885 |
| US-20110092668-A1 | AZIDE FUNCTIONALIZED PEPTIDE TARGETING GROUPS | IAPP, NGLY1, MSN | ILK 606/4885EGFR 54/4885ACACB 3933/4885 |
| US-20080009492-A1 | Heterocyclic Carbamate Derivatives, Their Manufacture And Use As Pharmaceutical Agents | RCC2, ACMSD, CPS1 | ILK 4225/4885EGFR 3427/4885ACACB 954/4885 |
| US-20110091534-A1 | COMPOSITIONS COMPRISING POLYMERIC MICELLES FOR DRUG DELIVERY | ABCB4, ABCB11, CLTB | ILK 150/4885EGFR 47/4885ACACB 1655/4885 |
| US-20080039460-A1 | Benzamide Derivatives, Their Manufacture and Use as Pharmaceutical Agents | TMBIM6, BAK1, CYP3A5 | ILK 4718/4885EGFR 1527/4885ACACB 1118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.